Database

TBD Criteria TBD

In the bustling neighbourhood of Washington Heights, New York, Alexandra Cohen learned the true value of community and the importance of giving back. From her mother's acts of kindness to the neighbours, she understood that change starts with one person. Today, that core belief drives the Steven & Alexandra Cohen Foundation's philanthropic endeavours across the United States.

This phase I/II trial (n=56) will study the safety and side effects of psilocybin in combination with therapy for treating cancer-related anxiety in patients with metastatic cancer. Psilocybin is being studied to treat anxiety or depression in patients with advanced cancer. Participants will receive psilocybin orally and participate in group and individual therapy sessions.

This randomized double-blind, active placebo-controlled trial (n=24) investigates the analgesic efficacy of esketamine on fibromyalgia pain. The study found short-term pain reduction in the ketamine group but no significant differences in treatment effects on pain scores during the 2.5-hour or the 8-week follow-up, suggesting that a short-term infusion of ketamine is insufficient for long-term analgesic effects in fibromyalgia patients.

This trial is registered with the Dutch trial registry that has been offline for over a year and hasn't been registered in any other database. We will update this record once it becomes available. All data are estimates.

This Phase I open-label trial (n=14) studied the safety of psilocybin when administered to healthy participants enrolled in a psychedelic-assisted therapy training program. Participants ingested 25 mg of psilocybin extract, and vital signs, including heart rate, blood pressure, temperature, and ECG, were monitored throughout the study.

This case presentation (n=1) describes a subject with red-green colour vision deficiency (mild deuteranomaly) who experienced a partial improvement in their condition after using 5g of dried psilocybin mushrooms. Self-reported Ishihara Test data showed the improvement peaking at 8 days and lasting at least 16 days post-administration, although further observations were confounded by other substance use.

This single-blind, placebo-controlled, crossover study (n=6) assessed the psychological effects and tolerability of ayahuasca (35, 52.5, 75mg DMT/70kg) in healthy male volunteers with prior experience. The study found dose-dependent increases in various psychological effects, with the tea being well-tolerated from a cardiovascular perspective, though modified physical sensations and nausea were the most frequently reported somatic-dysphoric effects. Ayahuasca induced changes in perceptual, affective, cognitive, and somatic spheres, with stimulatory and visual psychoactive effects of longer duration and milder intensity than intravenously administered DMT.

This re-analysis of the psilocybin (25mg) versus escitalopram (antidepressant, 6 weeks) RCT finds that in the psilocybin arm, experiential avoidance reductions led to improvements in mental health outcomes (e.g. depression severity). Note: the trial itself was insignificant on the primary measure of depression.

This systematized review (s=82) examines the current evidence for best therapeutic practices during administration sessions with serotonergic psychedelics and entactogens (e.g. MDMA) as adjuncts to psychotherapy. The study finds that the effects of different therapeutic models, methods, techniques, and more complex interventions on therapeutic outcomes have not been investigated rigorously, with most available evidence being anecdotal.